Ethical reflections on phase I clinical trials of anticancer drugs: from a Chinese IRB’s empirical perspective

被引：0

作者：

Xiaoling Liu ^{[1
]}

Zhengbo Song ^{[4
]}

Shuting Tang ^{[2
]}

Zhaochen Wang ^{[4
]}

Ji Zhu ^{[1
]}

机构：

[1] Zhejiang Cancer Hospital,The Medical Ethics Office

[2] The Phase I Clinical Trial Ward,Center for Bioethics

[3] Zhejiang Cancer Hospital,The Department of Radiotherapy

[4] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined

[5] The Institutional Review Board,undefined

[6] Zhejiang Cancer Hospital,undefined

[7] Zhejiang Cancer Hospital,undefined

来源：

Holistic Integrative Oncology | / 3卷 / 1期

关键词：

Anticancer drugs; Phase I clinical trials; Ethical review; Research participant protection;

D O I：

10.1007/s44178-024-00126-4

中图分类号：

学科分类号：

摘要：

引用

共 16 条

[1] Zhao S(2020)Risk management of phase I clinical trials of anticancer drugs Chin J New Drugs 29 749-752
[2] Liu X(2020)Discussion of holistic quality management for anti-tumor drugs in phase I clinical trials Chin J Clin Pharmacol 36 2510-2512
[3] Jiang M(2023)Retrospective analysis of protocol violation of anti-tumor drugs clinical trials from the perspective of ethical review Chinese Journal of New Drugs 32 2411-2416
[4] Liu L(2023)Analysis on Quality Control Reports of Phase I Clinical Trial of Anti-Tumor Drugs Evaluation and analysis of drug-use in hospitals of China 23 1139-1142
[5] Qi L(2020)Problems and Solutions in Ethical Tracking Review of Phase I Clinical Trials of New Drugs Chin Med Ethics 33 349-354
[6] Bai H(undefined)undefined undefined undefined undefined-undefined
[7] Wang X(undefined)undefined undefined undefined undefined-undefined
[8] Zhang L(undefined)undefined undefined undefined undefined-undefined
[9] Hao C(undefined)undefined undefined undefined undefined-undefined
[10] Li J(undefined)undefined undefined undefined undefined-undefined